XNCR · Xencor, Inc. · Stock research

KYMR

Kymera Therapeutics, Inc.

Oral STAT6 degrader (KT-621) re-rated on early BROADEN2 enrollment (6/25) and the $10.9B AbbVie–Apogee read-through, but the analyst upgrade cycle topped with RBC's 7/13 downgrade to neutral and the binary topline is 2H-2026 a maturing, stretched theme better bought on a pullback to the $100 shelf than chased into the catalyst gap.

SYRE

Spyre Therapeutics, Inc.

Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs SPY003 IL-23 Part A (guided mid-2026, overdue) and SPY072 RA topline (accelerated to Q3) are the near-term binaries. Platform de-risked, but distribution flags plus ~1:1 R/R to $100–135 targets argue probe-only into an all-time high.

TNGX

Tango Therapeutics, Inc.

Post-data digestion, not acceleration: the 92% ORR combo print is fully paid for and the tape has faded from $32.90 to ~$27.7, below the $30.00 June secondary. Sell-side keeps marking up (JPM Overweight $46 on 7/15, Mizuho $40 on 7/17) into a falling price a divergence that historically resolves toward price. Next hard data is ESMO in October.

PSNL

Personalis, Inc.

The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus two other suitors. Price broke to a $16.39 52-week high; Needham $17 and TD Cowen $18 now sit above the tape. Aug-4 Q2 is the next hard date.